The Medicines Company to pay up to $420 million for discontinued Pfizer CV candidate
This article was originally published in Scrip
Executive Summary
The Medicines Company has handed the potential anti-atherosclerotic ApoA-I Milano a new lease of life after acquiring the candidate from Pfizer for up to $420 million. The product's development had been abandoned and was unlikely to be revived under Pfizer's current strategy.